Orphan Drug Incentives Would Go Further Than Regulatory Reform - Reardan
Executive Summary
Eleos VP-Regulatory Affairs Dayton Reardan suggested that instead of focusing on problems with FDA's review process for rare disease drugs, government should create more development incentives in order to bring more drugs for rare diseases to market